Literature DB >> 9401506

Failure to thrive: the earliest feature of cystic fibrosis in infants diagnosed by neonatal screening.

L Giglio1, M Candusso, C D'Orazio, G Mastella, D Faraguna.   

Abstract

The benefits of early treatment of nutritional and respiratory problems in the CF infant and of genetic counselling for the parents are widely recognized. However, clinical diagnosis of CF is often delayed despite early onset of symptoms and the usefulness of neonatal population screening as a preventive measure is still under debate. This study analyses the clinical history of CF patients diagnosed exclusively on the basis of positive neonatal screening tests with the aim of identifying the earliest markers of the disease. We studied 103 CF infants born in north-east Italy, diagnosed following neonatal screening: assay of immunoreactive trypsin (IRT) from a heel-prick blood sample followed by a measurement of meconium lactase in cases with raised IRT. Diagnosis was confirmed by sweat test at an average age of 39 days. Eighty-one patients (79%) had symptoms strongly suggestive of CF at diagnosis, and signs and/or symptoms of pancreatic insufficiency were present in 16 of the remaining 22 cases. The most frequent symptom was growth failure (69% of infants) and of these, 44% weighed the same as at birth or less. Pancreatic insufficiency was confirmed by the low level of faecal chymotrypsin found in 85% of cases. IRT was elevated in all cases. CF had not been suspected in any symptomatic infant, although most of the infants had been monitored by a paediatrician. In conclusion, most infants with CF diagnosed by neonatal screening are already symptomatic in the first six weeks of life and the most frequent symptom is failure to thrive; pancreatic insufficiency was already present in most cases. In areas without CF neonatal screening programs, the disease should be excluded by differential diagnosis in all cases with growth failure notwithstanding adequate caloric intake in the first months of life. The high sensitivity, low cost and simple execution of IRT and fecal chymotrypsin tests make them an ideal first step in suspect cases before proceeding to the sweat test, often performed late because of limited availability.

Entities:  

Mesh:

Year:  1997        PMID: 9401506     DOI: 10.1111/j.1651-2227.1997.tb14836.x

Source DB:  PubMed          Journal:  Acta Paediatr        ISSN: 0803-5253            Impact factor:   2.299


  10 in total

1.  The need for vigilance: the case of a false-negative newborn screen for cystic fibrosis.

Authors:  Christina T Dunn; Mary M Skrypek; Amy L R Powers; Theresa A Laguna
Journal:  Pediatrics       Date:  2011-07-04       Impact factor: 7.124

2.  Comparing the Use of Centers for Disease Control and Prevention and World Health Organization Growth Charts in Children with Cystic Fibrosis through 2 Years of Age.

Authors:  Zhumin Zhang; Suzanne M Shoff; HuiChuan J Lai
Journal:  J Pediatr       Date:  2015-08-19       Impact factor: 4.406

3.  Sex differences in patients referred for evaluation of poor growth.

Authors:  Adda Grimberg; Jessica Katz Kutikov; Andrew J Cucchiara
Journal:  J Pediatr       Date:  2005-02       Impact factor: 4.406

4.  Recovery of birth weight z score within 2 years of diagnosis is positively associated with pulmonary status at 6 years of age in children with cystic fibrosis.

Authors:  Huichuan J Lai; Suzanne M Shoff; Philip M Farrell
Journal:  Pediatrics       Date:  2009-02       Impact factor: 7.124

Review 5.  Newborn screening for cystic fibrosis.

Authors:  Jack K Sharp; Michael J Rock
Journal:  Clin Rev Allergy Immunol       Date:  2008-12       Impact factor: 8.667

6.  Early attained weight and length predict growth faltering better than velocity measures in infants with CF.

Authors:  Sonya L Heltshe; Drucy S Borowitz; Daniel H Leung; Bonnie Ramsey; Nicole Mayer-Hamblett
Journal:  J Cyst Fibros       Date:  2014-06-07       Impact factor: 5.482

7.  Cystic Fibrosis Foundation evidence-based guidelines for management of infants with cystic fibrosis.

Authors:  Drucy Borowitz; Karen A Robinson; Margaret Rosenfeld; Stephanie D Davis; Kathryn A Sabadosa; Stephanie L Spear; Suzanne H Michel; Richard B Parad; Terry B White; Philip M Farrell; Bruce C Marshall; Frank J Accurso
Journal:  J Pediatr       Date:  2009-12       Impact factor: 4.406

Review 8.  Pathophysiology of cystic fibrosis and drugs used in associated digestive tract diseases.

Authors:  Adriana Haack; Giselle Gonçalves Aragão; Maria Rita Carvalho Garbi Novaes
Journal:  World J Gastroenterol       Date:  2013-12-14       Impact factor: 5.742

9.  Clinical and laboratory profile of children with Cystic Fibrosis: Experience of a tertiary care center in Pakistan.

Authors:  Danish Abdul Aziz; Abdul Gaffar Billoo; Ahad Qureshi; Misha Khalid; Salman Kirmani
Journal:  Pak J Med Sci       Date:  2017 May-Jun       Impact factor: 1.088

10.  Phenotypic spectrum and genetic heterogeneity of cystic fibrosis in Sri Lanka.

Authors:  Neluwa Liyanage Ruwan Indika; Dinesha Maduri Vidanapathirana; Hewa Warawitage Dilanthi; Grace Angeline Malarnangai Kularatnam; Nambage Dona Priyani Dhammika Chandrasiri; Eresha Jasinge
Journal:  BMC Med Genet       Date:  2019-05-24       Impact factor: 2.103

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.